Lack of cost-effectiveness of omalizumab [9] (multiple letters)

Journal of Allergy and Clinical Immunology

Volumn 115, Issue 2, 2005, Pages 429-430

  Miller, Thomas P ^a   Reeves, Mathew J ^a   Oba, Yuji ^b   Salzman, Gary A ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OMALIZUMAB;

ALLERGIC RHINITIS; ASTHMA; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LETTER; MEDICAL DECISION MAKING; MEDICAL LITERATURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; SCORING SYSTEM; VALIDATION PROCESS;

EID: 13444312008     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.10.049     Document Type: Letter

References (5)

1. Y. Oba G.A. Salzman Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma J Allergy Clin Immunol 114 2004 265 269
2. M.R. Gold J.E. Siegel L.B. Russell M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
3. S.D. Sullivan K.B. Weiss H. Lynn H. Mitchell M. Kattne P.J. Gergen for the National Cooperative Inner-City Asthma Study Investigators The cost-effectiveness of an inner-city asthma intervention for children J Allergy Clin Immunol 110 2002 576 581
4. S.D. Sullivan A. Elixhauser A.S. Buist K.B. Weiss J. Eisenberg National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care Am J Respir Crit Care Med 154 1996 S84 S95
5. D.A. Petitti Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine 2nd ed. 2000 Oxford University Press New York